Back

The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial

27 August 2018 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: ACS diagnosis and treatment Thrombosis, Platelets, and Coagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Long vs. short dual antiplatelet therapy in ACS patients treated with prasugrel or ticagrelor and coronary revascularization: a propensity score analysis from the RENAMI registry
Doctor F. Fioravanti (Milan, IT)
Abstract Slides
Presentation thumbnail
Exploring the value of the PRECISE-DAPT score after complex percutaneous coronary intervention to inform dual antiplatelet therapy duration decision-making.
Doctor F. Costa (Malaga, ES)
Abstract Slides
Presentation thumbnail
Diagnostic evaluation of a new high-sensitive point-of-care troponin I assay
Doctor N. Soerensen (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Diagnostic accuracy of high sensitive cardiac troponin T in patients with suspected acute coronary syndrome and severe chronic kidney disease
Doctor B. Alushi (Munich, DE)
Abstract Slides
Presentation thumbnail
Does complying guidelines matter?
Doctor I. Campos (Braga, PT)
Abstract Slides

Access the full session

Session thumbnail
ACS diagnosis and treatment

The Event

Event poster

ESC Congress 2018

27 August 2018 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources